**Hospital Center**

**Transfusion Guidelines: ADULT PLASMA**

**GUIDANCE STATEMENT**

These represent guidelines for plasma transfusion. These guidelines include conditions for which transfusion may be considered reasonable, but not mandatory, practice. The decision to transfuse should not be based solely on a single lab result and represents a clinical consideration that takes into account the potential benefits and risks of the transfusion.

One unit of plasma contains approximately 300 ml although the volume of each unit may vary. 10-15 ml/kg is the usual adult dose for plasma products. In a 70 kg patient this represents 3-4 units and will approximately increase coagulation factors by 15%.

Multiple studies have shown the PT/INR is a poor predictor of bleeding risk and many procedures can be safely carried out when the INR is mildly to moderately elevated.

Prothrombin complex concentrate (4-factor PCC) is now preferred for emergent warfarin reversal along with vitamin K according to the American College of Chest Physicians Guidelines. Plasma transfusion for non-emergent warfarin reversal is discouraged.

|  |
| --- |
| **Guideline by PT/INR threshold and clinical indication:**  ***Therapeutic Use of Plasma***   * Active bleeding before coagulation studies are available   + Massive hemorrhage protocol or massive transfusion protocol initiated   + Traumatic injury with hemodynamic instability (pre-MTP activation) * Bleeding patient with multiple factor deficiencies * Bleeding patient when a specific factor concentrate is not available * Thromboelastography (TEG) values suggest a deficiency of plasma clotting factors in patient with active bleeding * Portal Hypertensive Bleeding in Cirrhosis - *Correcting INR with plasma is not recommended, given that INR is not a reliable indicator of coagulation status in cirrhosis (2016 Practice Guidance by the American Association for the Study of Liver Diseases)* * Plasma exchange transfusion in thrombotic thrombocytopenic purpura * INR greater than 1.5 and intracranial hemorrhage; prothrombin complex concentrate unavailable or contraindicated   ***Prophylactic use of plasma***  ***Note****: Prophylactic use of plasma to reduce risk for bleeding prior to invasive procedures for patients with a prolonged PT/INR is not supported by strong evidence.*  ***Note****: Vitamin K alone or 4-factor PCC with vitamin K should be used instead of plasma in patients*  *receiving warfarin.*   * **Low risk (blood loss) procedures**    + INR in the range of 2.0-3.0, patient unresponsive to Vitamin K and undergoing low risk procedures (for full list refer to 2019 Society Interventional Radiology Guidelines) * **Surgical intervention** - INR greater than 2.0, patient unresponsive to Vitamin K * **High-risk procedures**   + INR greater than 1.8, patient unresponsive to vitamin K and undergoing high-risk procedures (for full list refer to 2019 Society Interventional Radiology Guidelines)   **\*Note:** TIPS and transjugular liver biopsy must often be performed at an INR > 1.8 in patients with hepatic coagulopathy. Data suggest that these patients may have normal thrombin generation and may be at lower bleeding risk than indicated by the INR. For TIPS, If INR is acutely elevated from baseline or >3.0, consider checking fibrinogen and if <100mg/dL give fibrinogen replacement (cryoprecipitate or fibrinogen concentrate). |

-----------------------------------------------------------------------------------------------------------------------------------

References:

1. [Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. *Transfusion*. 2006;46(8):1279-1285. doi.org/10.1111/j.1537-2995.2006.00891.x](https://onlinelibrary.wiley.com/doi/full/10.1111/j.1537-2995.2006.00891.x)
2. [Lauzier F, Cook D, Griffith L, Upton J, Crowther M. Fresh frozen plasma transfusion in critically ill patients. *Crit Care Med.* 2007;35:1655–59. doi: 10.1097/01.CCM.0000269370.59214.97](http://www.ncbi.nlm.nih.gov/pubmed/17522577)
3. [Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgery or invasive interventions: a phase 3B, open-label, non-inferiority, randomized trial. *Lancet.* 2015;385:2077-87. doi: 10.1016/S0140-6736(14)61685-8.](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61685-8/fulltext)
4. [Munoz M, Stensballe J, Ducloy-Bouthers A, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. *Blood Transfus*. 2019;17:112-136. doi: 10.2450/2019.0245-18.](http://www.bloodtransfusion.it/articolo.aspx?idart=003221&idriv=000142)
5. [Anglin CO, Spence JS, Warner MA, et al. Effects of platelet and plasma transfusion on outcome in traumatic brain injury patients with moderate bleeding diatheses. *J Neurosurg*. 2013;118:676-86. doi: 10.3171/2012.11.JNS12622](http://www.ncbi.nlm.nih.gov/pubmed/23259827)
6. [Matevosyan K, Madden C, Barnett SL, Beshay JE, Rutherford C, Sarode R. Coagulation factor levels in neurosurgical patients with mild prolongation of prothrombin time: effect on plasma transfusion therapy. *J* *Neurosurg*. 2011 Jan;114(1):3-7](http://www.ncbi.nlm.nih.gov/pubmed/20815699). doi: 10.3171/2010.7.JNS091699
7. [Haas B, Chittams JL, Trerotola SO. Large-bore tunneled central venous catheter insertion in patients with coagulopathy. *J Vasc Interv Radiol*. 2010;21:212-7](http://www.ncbi.nlm.nih.gov/pubmed/20123206). doi: 10.1016/j.jvir.2009.10.032.
8. [Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. *Transfusion*. 2012 Aug;52(8):1673-86. doi: 10.1111/j.1537-2995.2011.03515.x.](http://www.ncbi.nlm.nih.gov/pubmed/22257164)
9. [Muller M, Arbous MS, Spoelstra-de Man AM, et al. Transfusion of fresh-frozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial (CME). *Transfusion* 2015; 55(1): 26-35. doi.org/10.1111/trf.12750](about:blank)
10. [Green L, Bolton-Maggs P, Beattie C, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. *Br J Haematol*. 2018;181(1): 54-67. doi.org/10.1111/bjh.15167https:/doi.org/10.1111/bjh.15167](https://doi.org/10.1111/bjh.15167).
11. [Yates S, Gavva C, Agrawal D, Sarode R. How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures? *Transfusion*. 2016;56(4):791-798. doi.org/10.1111/trf.13495](https://doi.org/10.1111/trf.13495)

1. [Cardigan R, Green L. Thawed and liquid plasma – what do we know? *Vox Sanguinis*. 2015;109(1):1-10. doi: 10.1111/vox.12251.](https://onlinelibrary.wiley.com/doi/abs/10.1111/vox.12251)
2. [Backholer L, Green L, Huish S, et al. A paired comparison of thawed and liquid plasma. *Transfusion*. 2017; 57(4):881-889. https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.13915](about:blank)
3. [Huebner BR, Moore EE, Moore HB, et al. 14-Day thawed plasma retains clot enhancing properties and inhibits tPA-induced fibrinolysis. *Journal of Surgical Research*. 2017;219:145-150. doi.org/10.1016/j.jss.2017.05.030](http://dx.doi.org/10.1016/j.jss.2017.05.030)
4. [Neisser-Svae A, Trawnicek L, Heger A, et al. Five-day stability of thawed plasma: solvent/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours. *Transfusion*. 2016; 56(2):404-409. doi.org/10.1111/trf.13356](http://doi.org/10.1111/trf.13356)
5. [Erickson A, Waldhaus K, David T, et al. Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6⁰C. *Transfusion*. 2017;57(4): 997-1006. doi.org/10.1111/trf.13973](https://doi.org/10.1111/trf.13973)
6. [Degos V, Westbroek E, Lawton, M, Hemphill JC 3rd, Del Zoppo GJ, Young WL. Perioperative management of coagulation in nontraumatic intracerebral hemorrhage. *Anesthesiology*. 2013;119(1):218-224. doi:10.1097/ALN.0b013e318297c18a.](http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918328)
7. Davidson JC, Rahim S, Hanks SE, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations. *J Vasc Interv Radiol.* 2019;30:1155-1167.
8. Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. *J Vasc Interv Radiol.* 2019;30:1168-1184.
9. [Zhang LM, Li R, Zhao XC, Zhang Q, Luo XL. Increased transfusion of fresh frozen plasma is associated with mortality or worse functional outcomes after severe traumatic brain injury: a retrospective study*.* *World Neurosurg*. 2017; 104:381-389. doi:10.1016/j.wneu.2017.04.140.](https://www.sciencedirect.com/science/article/abs/pii/S1878875017306484?via%3Dihub)
10. [Stolla M, Zhang F, Meyer MR, Zhang J, Dong JF. Current state of transfusion in traumatic brain injury and associated coagulopathy. *Transfusion*. 2019;59:1522-1528. doi: 10.1111/trf.15169.](https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15169)